| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology [A. K. S., J. E. C., S. J.], Department of Anatomy and Cell Biology [E. A. S., L. M. G., N. A., Z. K. E., M. J. C. H.], Department of Pathology [M. S. F.] and the Holden Comprehensive Cancer Center [A. K. S., E. A. S., Z. K. E., M. J. C. H.], University of Iowa, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242-1109
Maspin is a noninhibitory member of the serpin family that is down-regulated in breast carcinoma but overexpressed in pancreatic carcinoma. There are no published data regarding the role of maspin in ovarian carcinoma, which is the focus of the present study. Ovarian cell lines (normal and cancer) and tumors (80 invasive, 14 benign, and 10 low malignant potential) were evaluated for maspin expression and localization. Normal ovarian surface epithelial cells had low levels of maspin. Two of four ovarian cancer cell lines (OVCAR3 and SKOV3) expressed maspin, whereas the cell line EG had weak expression, and 222 had no detectable maspin. Subcellular fractionation studies revealed that the two maspin-positive ovarian cancer cell lines contained maspin in both the nuclear and cytosolic compartments. Wild-type maspin was transfected into the aggressive ovarian cancer cell lines SKOV3 and 222. The in vitro invasive activity of the maspin-transfected cell lines was 44–68% lower than respective controls. The histopathology analysis revealed that among the ovarian tumors examined, 57 (71%) were ranked positive for maspin. Thirty (37%) of the invasive tumors overexpressed maspin. Invasive cancers were more likely to have predominantly cytoplasmic staining compared with benign and low-malignant-potential tumors. Maspin overexpression was significantly associated with a high tumor grade (P = 0.004), the presence of ascites (P = 0.02), a lower likelihood of optimal surgical cytoreduction (P = 0.04), and a shorter duration of overall survival (median survival, 6.33 versus 2.67 years; P = 0.003). The Cox proportional hazards multivariate model revealed that maspin overexpression and high stage were independent predictors of survival. Thus, maspin was found to be overexpressed in a substantial proportion of ovarian tumors, which may serve as an adverse prognostic factor; however, its localization may provide new clues as to its activity and function. These paradoxical results may offer new insights regarding the role of maspin in ovarian cancer progression that may also impact diagnosis and treatment strategies.
This article has been cited by other articles:
|
|
 |
|
  M. Woenckhaus, L. Bubendorf, P. Dalquen, J. Foerster, H. Blaszyk, M. Mirlacher, M. Soler, W. Dietmaier, G. Sauter, A. Hartmann, et al. Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancer J. Clin. Pathol., May 1, 2007; 60(5): 483 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mhawech-Fauceglia, P. Dulguerov, A. Beck, M. Bonet, and A. S Allal Value of ezrin, maspin and nm23-H1 protein expressions in predicting outcome of patients with head and neck squamous-cell carcinoma treated with radical radiotherapy J. Clin. Pathol., February 1, 2007; 60(2): 185 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nakagawa, H. Katakura, M. Adachi, K. Takenaka, K. Yanagihara, Y. Otake, H. Wada, and F. Tanaka Maspin Expression and Its Clinical Significance in Non-Small Cell Lung Cancer Ann. Surg. Oncol., November 1, 2006; 13(11): 1517 - 1523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Nazarenko, G. Kristiansen, S. Fonfara, R. Guenther, C. Gieseler, W. Kemmner, R. Schafer, I. Petersen, and C. Sers H-REV107-1 Stimulates Growth in Non-Small Cell Lung Carcinomas via the Activation of Mitogenic Signaling Am. J. Pathol., October 1, 2006; 169(4): 1427 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Kamat, M. Fletcher, L. M. Gruman, P. Mueller, A. Lopez, C. N. Landen Jr., L. Han, D. M. Gershenson, and A. K. Sood The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer Clin. Cancer Res., March 15, 2006; 12(6): 1707 - 1714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Maesawa, S Ogasawara, A Yashima-Abo, T Kimura, K Kotani, S Masuda, Y Nagata, T Iwaya, K Suzuki, T Oyake, et al. Aberrant maspin expression in gallbladder epithelium is associated with intestinal metaplasia in patients with cholelithiasis. J. Clin. Pathol., March 1, 2006; 59(3): 328 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Y. Han, C. N. Landen Jr, A. A. Kamat, A. Lopez, D. P. Bender, P. Mueller, R. Schmandt, D. M. Gershenson, and A. K. Sood Preoperative Serum Tissue Factor Levels Are an Independent Prognostic Factor in Patients With Ovarian Carcinoma J. Clin. Oncol., February 10, 2006; 24(5): 755 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Shellenberger, A. Mazumdar, Y. Henderson, K. Briggs, M. Wang, C. Chattopadhyay, A. Jayakumar, M. Frederick, and G. L. Clayman Headpin: A Serpin with Endogenous and Exogenous Suppression of Angiogenesis Cancer Res., December 15, 2005; 65(24): 11501 - 11509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Dong, L T Bui, D M Odorico, O L Tan, S A Myers, H Samaratunga, R A Gardiner, and J A Clements Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms Endocr. Relat. Cancer, December 1, 2005; 12(4): 875 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Espinosa de los Monteros, M. Y. Millan, G. A. Ramirez, J. Ordas, C. Reymundo, and J. Martin de las Mulas Expression of Maspin in Mammary Gland Tumors of the Dog Vet. Pathol., May 1, 2005; 42(3): 250 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Latha, W. Zhang, N. Cella, H. Y. Shi, and M. Zhang Maspin Mediates Increased Tumor Cell Apoptosis upon Induction of the Mitochondrial Permeability Transition Mol. Cell. Biol., March 1, 2005; 25(5): 1737 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hirai, K. Koizumi, S. Haraguchi, T. Hirata, I. Mikami, M. Fukushima, S. Yamagishi, T. Kawashima, D. Okada, K. Shimizu, et al. Prognostic Significance of the Tumor Suppressor Gene Maspin in Non-Small Cell Lung Cancer Ann. Thorac. Surg., January 1, 2005; 79(1): 248 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kim, J. Han, J. Kim, and C. Park Maspin Expression Is Transactivated by p63 and Is Critical for the Modulation of Lung Cancer Progression Cancer Res., October 1, 2004; 64(19): 6900 - 6905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Sood, J. E. Coffin, G. B. Schneider, M. S. Fletcher, B. R. DeYoung, L. M. Gruman, D. M. Gershenson, M. D. Schaller, and M. J.C. Hendrix Biological Significance of Focal Adhesion Kinase in Ovarian Cancer: Role in Migration and Invasion Am. J. Pathol., October 1, 2004; 165(4): 1087 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, S. Yin, N. Reddy, C. Spencer, and S. Sheng Bax Mediates the Apoptosis-Sensitizing Effect of Maspin Cancer Res., March 1, 2004; 64(5): 1703 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. van Hensbergen, H. J. Broxterman, S. Rana, P. J. van Diest, M. C. A. Duyndam, K. Hoekman, H. M. Pinedo, and E. Boven Reduced Growth, Increased Vascular Area, and Reduced Response to Cisplatin in CD13-Overexpressing Human Ovarian Cancer Xenografts Clin. Cancer Res., February 1, 2004; 10(3): 1180 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Khalkhali-Ellis, A. L. Christian, D. A. Kirschmann, E. M. Edwards, M. Rezaie-Thompson, M. A. Vasef, L. M. Gruman, R. E. B. Seftor, L. E. Norwood, and M. J. C. Hendrix Regulating the Tumor Suppressor Gene Maspin in Breast Cancer Cells: A Potential Mechanism for the Anticancer Properties of Tamoxifen Clin. Cancer Res., January 15, 2004; 10(2): 449 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Akiyama, C. Maesawa, S. Ogasawara, M. Terashima, and T. Masuda Cell-Type-Specific Repression of the Maspin Gene Is Disrupted Frequently by Demethylation at the Promoter Region in Gastric Intestinal Metaplasia and Cancer Cells Am. J. Pathol., November 1, 2003; 163(5): 1911 - 1919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Lefter, M. Sunamura, T. Furukawa, K. Takeda, N. Kotobuki, M. Oshimura, S. Matsuno, and A. Horii Inserting Chromosome 18 into Pancreatic Cancer Cells Switches Them to a Dormant Metastatic Phenotype Clin. Cancer Res., October 15, 2003; 9(13): 5044 - 5052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Lutgendorf, S. Cole, E. Costanzo, S. Bradley, J. Coffin, S. Jabbari, K. Rainwater, J. M. Ritchie, M. Yang, and A. K. Sood Stress-Related Mediators Stimulate Vascular Endothelial Growth Factor Secretion by Two Ovarian Cancer Cell Lines Clin. Cancer Res., October 1, 2003; 9(12): 4514 - 4521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Re Intracellular Renin and the Nature of Intracrine Enzymes Hypertension, August 1, 2003; 42(2): 117 - 122. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
